Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
XTalks
AUGUST 17, 2020
protein-based biologics) and vaccine treatments. Treatment vaccines : these boost the immune system responses to target cells. Targeting HPV-Induced Head and Neck Cancer. Cue Biopharma’s lead compound, CUE-101, is designed to specifically engage and activate T cells in the body to target HPV-driven cancers.
98 
Let's personalize your content